Growth Metrics

ARS Pharmaceuticals (SPRY) Invested Capital (2021 - 2025)

Historic Invested Capital for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $247.7 million.

  • ARS Pharmaceuticals' Invested Capital rose 2322.49% to $247.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $247.7 million, marking a year-over-year increase of 2322.49%. This contributed to the annual value of $256.8 million for FY2024, which is 1128.36% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Invested Capital of $247.7 million as of Q3 2025, which was up 2322.49% from $192.3 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Invested Capital ranged from a high of $369.0 million in Q1 2021 and a low of -$31.3 million during Q4 2021
  • In the last 5 years, ARS Pharmaceuticals' Invested Capital had a median value of $248.6 million in 2023 and averaged $246.1 million.
  • The largest annual percentage gain for ARS Pharmaceuticals' Invested Capital in the last 5 years was 97270.46% (2022), contrasted with its biggest fall of 2054.33% (2022).
  • ARS Pharmaceuticals' Invested Capital (Quarter) stood at -$31.3 million in 2021, then surged by 972.7% to $272.9 million in 2022, then fell by 15.44% to $230.8 million in 2023, then increased by 11.28% to $256.8 million in 2024, then fell by 3.56% to $247.7 million in 2025.
  • Its last three reported values are $247.7 million in Q3 2025, $192.3 million for Q2 2025, and $229.0 million during Q1 2025.